Publications by authors named "Tracy Westley"
Article Synopsis
- Deucravacitinib, an oral tyrosine kinase 2 inhibitor, is approved globally for treating adults with moderate to severe plaque psoriasis, especially those needing systemic therapy.
- A systematic review and meta-analysis analyzed its efficacy in Asian populations compared to other treatments, revealing significant improvement over placebo and apremilast.
- In Asian patients, deucravacitinib showed PASI 75 and 90 response rates that are comparable to several biologics, highlighting its effectiveness and convenience as an oral treatment option.
Article Synopsis
- - Deucravacitinib is a newly approved oral medication for moderate to severe plaque psoriasis, showing better efficacy than apremilast and placebo in two phase 3 clinical trials.
- - A systematic review and network meta-analysis compared deucravacitinib with various systemic therapies, finding that it had the highest PASI 75 response rates among nonbiologic systemic treatments at different follow-up periods.
- - Patients taking deucravacitinib had higher chances of achieving significant improvement (PASI 75 response) compared to those treated with apremilast and methotrexate, particularly over mid- and long-term follow-ups.
Introduction: Tafasitamab plus lenalidomide (TAFA + LEN) received accelerated US Food and Drug Administration approval and conditional European Medicines Agency approval for treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) not eligible for autologous stem cell transplant. This study investigates the relative efficacy of TAFA + LEN versus comparator treatments.
Methods: Matching-adjusted indirect comparisons (MAICs) of TAFA + LEN were performed using data from L-MIND, and comparator studies assessing rituximab-based combination therapies, including polatuzumab vedotin + bendamustine + rituximab (POLA + BR) bendamustine + rituximab (BR), and gemcitabine + oxaliplatin + rituximab (R-GEMOX) to provide relative efficacy estimates for overall survival (OS), progression-free survival (PFS), duration of response (DOR), objective response rate (ORR), and complete response rate (CRR).
Indirect treatment comparisons are used when no direct comparison is available. Comparison networks should satisfy the transitivity assumption, that is, equal likelihood of treatment assignment for a given patient based on comparability of studies. Seven criteria were evaluated across 18 randomized controlled trials in psoriatic arthritis: inclusion/exclusion criteria, clinical trial design and follow-up, patient-level baseline characteristics, disease severity, prior therapies, concomitant and extended-trial treatment and placebo response differences.
View Article and Find Full Text PDFBackground: Until recently, treatments for older patients with AML ineligible to receive intensive chemotherapies were limited to hypomethylating agents, low-dose cytarabine (LDAC), or clinical trials. In 2018, the FDA approved combination glasdegib (GLAS) plus LDAC based on Phase II results demonstrating improved overall survival (OS) versus LDAC alone in previously untreated AML. However, no randomized clinical trials have directly compared GLAS + LDAC with other AML treatments.
View Article and Find Full Text PDFBackground: In the absence of clinical trials providing direct efficacy results, this study compares different methods of indirect treatment comparison (ITC), and their respective impacts on efficacy estimates for lenvatinib (LEN) plus everolimus (EVE) combination therapy compared to other second-line treatments for advanced/metastatic renal cell carcinoma (a/mRCC).
Methods: Using EVE alone as the common comparator, the Bucher method for ITC compared LEN + EVE with cabozantinib (CAB), nivolumab (NIV), placebo (PBO) and axitinib (AXI). Hazard ratios (HR) for overall survival (OS) and progression-free survival (PFS) estimated the impact of applying three versions of the LEN+EVE trial data in separate ITCs.
Purpose: Older Breast Cancer (BC) survivors are an increased risk of osteoporosis due to natural aging and long-term cancer treatment-related toxicity. It is well known that anti-estrogen therapy (AET), especially aromatase inhibitors (AI), is associated with rapid bone loss and thus increases the risk of osteoporosis. This study characterizes patterns and predictors of receiving guideline-recommended bone densitometry (BD) screening at AET initiation.
View Article and Find Full Text PDFObjectives: To characterize rates, reasons for, and associated predictors for emergency department (ED) visits after breast cancer (BC) surgery.
Methods: All women over 65 years undergoing curative surgery for non-metastatic incident BC (1998-2012) were identified using Quebec's universal healthcare administrative databases. Reasons for ED visits within 45days of operation were reported.
Neighborhood socioeconomic conditions and depression: a systematic review and meta-analysis.
Soc Psychiatry Psychiatr Epidemiol
November 2015
Purpose: The evidence linking neighborhood socioeconomic conditions (NSEC) with depression is mixed. We performed a systematic review of this literature, including a rigorous quality assessment that was used to explore if methodological or contextual factors explained heterogeneity across studies.
Methods: A systematic literature search in three databases identified longitudinal studies among adolescents and adults living in high-income countries.